A field activity that the US Food and Drug Administration has since temporarily suspended due to COVID-19 led to a warning letter noting findings rarely seen during the pandemic – good manufacturing practices violations by a dietary supplement firm.
The agency’s Office of Regulatory Affairs West Division 6 stated in a warning posted on FDA’s website on 4 January...





